AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00757887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Exposure to 5 P. falciparum infected mosquitoes
Description: Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
Study NCT00757887 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to 5 P. falciparum infected mosquitoes
Description: Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
Study NCT00945269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: denileukin diftitox
Description: Given IV
Study NCT00945269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Optional correlative studies
Study NCT01034254 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: influenza vaccine
Description: Pregnant women will receive FDA approved influenza vaccine.
Study NCT01034254 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Vaccination of pregnant women with saline placebo.
Study NCT02909283 — intervention group
Intervention type: PROCEDURE
Intervention: Physical exams and blood analyzes
Description: Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
Study NCT00527553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: not enriched egg
Description: daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
Study NCT00527553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein
Description: daily lutein enriched egg
Study NCT00527553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zeaxanthin
Description: daily zeaxanthin enriched egg
Study NCT00527553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: egg product from enriched eggs
Description: daily egg product from lutein enriched eggs
Study NCT00296231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal high frequency ventilation
Description: use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
Study NCT03562559 — intervention group
Intervention type: OTHER
Intervention: Measurements Using Ultrasound
Description: Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
Study NCT01615237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audit and performance feedback (PF)
Description: Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
Study NCT01615237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial Incentive (P4P)
Description: We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Study NCT00945269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT03273595 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Study NCT03273595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02943278 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Sleep Retraining
Description: Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
Study NCT01615237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Best Practices (CBP)
Description: CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
Study NCT02943278 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Hygiene
Description: Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
Study NCT01157260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin
Description: AST-120 2g three times a day
Study NCT00121745 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 1
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
Study NCT00121745 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 2
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
Study NCT00121745 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 3
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml
Study NCT00121745 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 4
Description: Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml
Study NCT00945269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00945269 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT00546936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5mg ranibizumab
Study NCT00546936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: verteporfin
Description: Photodynamic therapy with verteporfin every 3 months for 1 year
Study NCT00846352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Variation in the time for performing bronchoscopy
Description: The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
Study NCT02616055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesevatinib
Study NCT04380558 — intervention group
Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: Patients will be asked to answer two questionnaires about urinary incontinence symptoms (see outcomes) to assess the prevalence and the type of these symptoms.~They will subsequently participate in their usual pulmonary rehabilitation program consisting in 90min sessions (including endurance training, muscle strengthening and self-management), 3x/week for 8weeks (centre 1) or 2x60min sessions (including the same components), 3x/week for 8weeks (centre 2).
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: 2 mg oral lorazepam
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: 2 mg oral lorazepam
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 20 ml 1% buffered lidocaine, injected
Study NCT01330459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 20 ml 1% buffered lidocaine, injected
Study NCT01568060 — intervention group
Intervention type: OTHER
Intervention: Infanrix-IPV data collection
Description: Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
Study NCT03675230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomotherapy HD
Description: Patients with Medulloblastoma receiving Tomotherapy
Study NCT03675230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3DCRT
Description: Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
Study NCT00128050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFactor VIIa (Eptacog alfa, NovoNordisk)
Description: rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
Study NCT00128050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFVIIa
Description: Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
Study NCT00128050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodiun chloride 0.9%
Description: Bolus injection of sodium chloride 0.9% after surgical hematoma removal
Study NCT04636164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Model Dermatology (deep neural networks; Build 2020)
Description: Physicians in the DNN group take pictures of the skin lesion and use the algorithm by uploading pictures.
Study NCT00752011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-106
Description: Starting dose 2.0 mg/m\^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
Study NCT00752011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
Study NCT00853463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Alert
Description: The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
Study NCT03544710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative bathing with antiseptic
Description: Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team.
Study NCT01902368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: gluten free diet
Study NCT02743338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
Study NCT02743338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Restriction
Description: Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
Study NCT02743338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Compression
Description: Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
Study NCT01866215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycling at 100W during 60 min
Study NCT01866215 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fructose
Description: isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
Study NCT02743338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Additional CBT-i components
Description: After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
Study NCT02743338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional CBT-i components
Description: After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
Study NCT02701270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Dietary Fibre 1
Description: 22.17 g of product diluted in 250 ml of water taken once orally.
Study NCT02701270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Dietary Fibre 2
Description: 21.84 g of product diluted in 250 ml of water taken once orally.
Study NCT02701270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polydextrose
Description: 21.48 g of product diluted in 250 ml of water taken once orally.
Study NCT02701270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose
Description: 23.89 g of dextrose diluted in 250 ml of water taken once orally.
Study NCT04236323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Not used remifentanil infusion
Description: Remifentanil is not used during operation
Study NCT02908048 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples collected at varying intervals over a two to three year period.
Study NCT01010776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Extended Release (ER)
Description: Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
Study NCT02240992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PBSC
Study NCT02240992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSCs
Study NCT04286711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-paclitaxel, Apatinib, Camrelizumab
Description: Albumin-paclitaxel: ivgtt, 75 or 100 or 125mg /m2, d1, d8, Repeat the therapeutic schedule every 3 weeks; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day); Camrelizumab：ivgtt, 200mg, given on the first day, Q3W;
Study NCT00371397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga Classes
Description: Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
Study NCT00371397 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Movement Control
Description: Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
Study NCT03828916 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NuShield
Description: SOC surgery with the addition of NuShield
Study NCT03929276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-intensity laser therapy & exercises
Description: A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
Study NCT03929276 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Shame laser & exercises
Description: Sham laser treatment (the same device to be used, 0 watts) will be given.
Study NCT03929276 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
Study NCT03929276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
Study NCT03929276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Therapeutic exercises All participants received 25-minutes of passive stretching, active assisted range of motion and codman pendicular exercises (10 repetitions, 3 sets, 3-minutes rest between sets) to the shoulder joint, supervised by the same physiotherapist five times a week for 3 weeks.
Study NCT00855179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Red vine leaf extract (AS 195)
Description: Antistax film-coated tablet 360 mg